SEC Filing Summary: Landec Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc.) on September 29, 2021. The filing reports the consolidated financial results for the first quarter of fiscal year 2022, which ended on August 29, 2021. The Company's common stock trades on the NASDAQ Global Select Market under the symbol LNDC.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It only confirms the announcement of Q1 FY2022 results.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, or contingencies. It explicitly states that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific financial results (revenue, net income, EPS) in the attached Exhibit 99.1 Press Release, as they are not listed in the 8-K body.
- Confirm the fiscal quarter end date of August 29, 2021 for accurate period comparison.
- Note that the registrant is Landec Corporation, distinct from the company name mentioned in the request metadata.
- Review the press release for any non-GAAP measures or unusual items that may impact financial interpretation.